Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts remain broadly positive: Oruka Therapeutics has a “Moderate Buy” consensus, with 10 buy ratings and 1 sell rating. The average 12-month price target is $133, although targets range from $120 to $200.
• Shares are trading near recent highs: ORKA opened at $92.38, up 0.8%, with a market capitalization of approximately $6.12 billion and a 52-week range of $14.66 to $115.51.
• Recent results and insider activity warrant attention: The company reported a quarterly loss of $0.55 per share, missing estimates by $0.04, while insiders sold roughly $10.4 million of stock over the past 90 days. Institutional investors own 56.44% of the shares.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $133.00.

ORKA has been the topic of several research reports. Wedbush restated an "outperform" rating and set a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. BTIG Research reiterated a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. Mizuho set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, Guggenheim restated a "buy" rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th.

Oruka Therapeutics Trading Up 0.8%

ORKA opened at $92.38 on Friday. The business has a 50 day moving average of $95.46 and a 200-day moving average of $71.68. The stock has a market capitalization of $6.12 billion, a price-to-earnings ratio of -45.51 and a beta of -0.34. Oruka Therapeutics has a 1-year low of $14.66 and a 1-year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Equities analysts predict that Oruka Therapeutics will post -2.42 EPS for the current year.

Insider Activity

In related news, CEO Lawrence Klein sold 75,000 shares of the firm's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company's stock, valued at $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Monday, August 17th. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00. Following the sale, the insider owned 32,718 shares in the company, valued at $3,659,181.12. This represents a 17.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 113,657 shares of company stock worth $10,410,003. Company insiders own 23.49% of the company's stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. grew its holdings in shares of Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company's stock worth $1,120,000 after purchasing an additional 13,164 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Oruka Therapeutics in the first quarter valued at about $5,543,000. Handelsbanken Fonder AB bought a new position in shares of Oruka Therapeutics in the second quarter valued at about $15,313,000. The Manufacturers Life Insurance Company lifted its position in Oruka Therapeutics by 18.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company's stock worth $3,559,000 after buying an additional 11,205 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in Oruka Therapeutics during the 2nd quarter worth about $474,916,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.